Abstract Number: L12 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors
Background/Purpose: TNF inhibitors (TNFi) are recommended for patients with axial SpA (axSpA) who do not respond to or tolerate NSAIDs. Some patients are inadequate responders…Abstract Number: 605 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in patients (pts.) with active RA after treatment with at least one TNFi in a RCT. However,…Abstract Number: 1503 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model
Background/Purpose: Discontinuation of tumor necrosis factor inhibitor (TNFi) therapy in rheumatoid arthritis (RA) is attributable to various reasons. Above all, adverse event (AE) and insufficient…Abstract Number: 2455 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Treated with Biologic and Non-Biologic Dmards
Background/Purpose: Individuals with rheumatoid arthritis (RA) have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), compared with…Abstract Number: 2613 • 2018 ACR/ARHP Annual Meeting
Patterns of Medication Use in a Validated Cohort of Psoriatic Arthritis (PsA) Patients
Background/Purpose: There is currently a lack of consensus among experts on the optimal therapeutic management of psoriatic arthritis (PsA). EULAR and GRAPPA recommendations support initial…Abstract Number: 610 • 2018 ACR/ARHP Annual Meeting
4 Years Follow-up of a Cohort of Patients with Rheumatoid Arthritis in Sustained Clinical Remission with Optimization of Biological Therapy
Background/Purpose: Once sustained clinical remission is achieved under tratment with biological therapies, the most efficient strategy is optimization. Searching for the lowest effective dose for…Abstract Number: 1597 • 2018 ACR/ARHP Annual Meeting
Bone Mineral Density and Serum Biomarkers of Bone Turnover in Ankylosing Spondylitis Patients Treated with Secukinumab: 2-Year Data from the Pivotal Phase 3 Study
Background/Purpose: Low bone mass is common in ankylosing spondylitis (AS) and patients (pts) with AS have an increased risk of bone fracture.1-3 Treatment of AS…Abstract Number: 2484 • 2018 ACR/ARHP Annual Meeting
Effect of Biologic Agents on Synovial Tissues from Patients with Rheumatoid Arthritis
Background/Purpose: Multiple studies addressing the effects of biologics on the synovial tissue in rheumatoid arthritis (RA) patients have been reported. There are, however, few studies…Abstract Number: 2624 • 2018 ACR/ARHP Annual Meeting
Cost-Effectiveness of Swapping Strategy for Established Psoriatic Arthritis and Immediate Versus Standard Swapping Strategy for Early Psoriatic Arthritis
Background/Purpose: For patients with psoriatic arthritis (PsA) failing the first TNF-inhibitor, switching to biologic DMARDs [bDMARDs] with different mechanism of actions (swapping strategy) may be…Abstract Number: 624 • 2018 ACR/ARHP Annual Meeting
Easy Accessibility of Biologics and Its Impact on Disease Activity and Quality of Life in Kuwaiti Patients with Rheumatoid Arthritis
Background/Purpose: Prescribing biologics for patients with rheumatoid arthritis (RA) may be restricted by many factors other than the physician’s clinical judgment. In Kuwait, patients with…Abstract Number: 1663 • 2018 ACR/ARHP Annual Meeting
Correlation between Biologics and Bath Ankylosing Spondylitis Metrology Index within the First 12 Months of Treatment in Patients with Axial Spondyloarthritis
Background/Purpose: Several studies demonstrate efficacy of biologics on disease activity measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritides…Abstract Number: 2515 • 2018 ACR/ARHP Annual Meeting
Joint Damage Progression According to Disease Activity States in Patients with Rheumatoid Arthritis Treated with CT-P10 and Reference Rituximab: Up to 48 Weeks Results from Phase III Study
Background/Purpose: CT-P10 is a biosimilar of the reference rituximab (RTX) and has been approved by several regulatory agencies including EMA. Pharmacokinetic and therapeutic equivalence from…Abstract Number: 2658 • 2018 ACR/ARHP Annual Meeting
Real World Medication Use in Incident Systemic Lupus Erythematosus and Lupus Nephritis Patients
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that causes inflammation in connective tissues and can involve multiple organs systems. Lupus nephritis (LN) is…Abstract Number: 628 • 2018 ACR/ARHP Annual Meeting
Longitudinal Changes in Relative Market Share Proportions of Biologic and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs for Treatment of Rheumatoid Arthritis: Descriptive Data from the Ontario Best-Practice Research Initiative Database
Background/Purpose: For patients with Rheumatoid Arthritis (RA) who do not achieve adequate clinical response with combined conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), the next…Abstract Number: 1829 • 2018 ACR/ARHP Annual Meeting
Perturbations of the Gut Fungal and Bacterial Microbiome with Biologic Therapy in Spondyloarthritis
Background/Purpose: The microbiome serves a number of important functions, including modulation of the immune system and protection from pathogenic microorganisms1. Many autoimmune diseases have been…
- 1
- 2
- 3
- …
- 26
- Next Page »